Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe ; day:23 ; month:5 ; year:2016 ; pages:1-13
Rheumatology and therapy ; (23.5.2016), 1-13
- Urheber
-
Thakur, Kunal
- Beteiligte Personen und Organisationen
-
Biberger, Anna
Handrich, Alexandra
Rezk, Mourad Farouk
SpringerLink (Online service)
- DOI
-
10.1007/s40744-016-0035-1
- URN
-
urn:nbn:de:1111-2016052420838
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Thakur, Kunal
- Biberger, Anna
- Handrich, Alexandra
- Rezk, Mourad Farouk
- SpringerLink (Online service)
Ähnliche Objekte (12)
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic
Etanercept-Induced Anti-Glomerular Basement Membrane Disease
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic
Etanercept-Induced Anti-Glomerular Basement Membrane Disease
Erratum to: Perceptions and Preferences of Two Etanercept Autoinjectors for Rheumatoid Arthritis: A New European Union-Approved Etanercept Biosimilar (Benepali®) Versus Etanercept (Enbrel®) - Findings from a Nurse Survey in Europe
Correction to: GP2015: An Etanercept Biosimilar
Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
Afebriles Erysipel unter Etanercept-Therapie
Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study
Etanercept may induce neurosarcoidosis in a patient treated for rheumatoid arthritis
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept and venous thromboembolism: a case series
Perispinal etanercept: Potential as an Alzheimer therapeutic